Statement of Principles concerning Hodgkin lymphoma (Balance of Probabilities) (No. 71 of 2023)

Administered by Department of Veterans' Affairs

Legislation au F2023L00950 In force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

STATEMENT OF PRINCIPLES CONCERNING

HODGKIN LYMPHOMA

(BALANCE OF PROBABILITIES) (NO. 71 OF 2023)

 

VETERANS' ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

  1. This is the Explanatory Statement to the Statement of Principles concerning Hodgkin lymphoma (Balance of Probabilities) (No. 71 of 2023).

Background

2.             The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), repeals Instrument No. 75 of 2014 (Federal Register of Legislation No. F2014L00468) determined under subsection 196B(3) of the VEA concerning Hodgkin's lymphoma.

3.             The Authority is of the view that on the sound medical-scientific evidence available it is more probable than not that Hodgkin lymphoma and death from Hodgkin lymphoma can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(3) of the VEA a Statement of Principles concerning Hodgkin lymphoma (Balance of Probabilities) (No. 71 of 2023).  This Instrument will in effect replace the repealed Statement of Principles.

Purpose and Operation

4.             The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

5.             The Statement of Principles sets out the factors that must exist, and which of those factors must be related to the following kinds of service rendered by a person:

 eligible war service (other than operational service) under the VEA;

 defence service (other than hazardous service and British nuclear test defence service) under the VEA;

 peacetime service under the MRCA,

before it can be said that, on the balance of probabilities, Hodgkin lymphoma or death from Hodgkin lymphoma is connected with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

6.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 2 November 2021 concerning Hodgkin's lymphoma in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

7.             The contents of this Instrument are in similar terms as the repealed Instrument.  Comparing this Instrument and the repealed Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2015;
  • specifying a day of commencement for the Instrument in section 2;
  • revising the definition of 'Hodgkin lymphoma' in subsection 7(2);
  • including ICD-10-AM codes for 'Hodgkin lymphoma' in subsection 7(3);
  • revising the reference to 'ICD-10-AM code' in subsection 7(4);
  • revising the factor in subsection 9(1) concerning having smoked tobacco products;
  • revising the factor in subsection 9(2) concerning being obese;
  • revising the factor in subsection 9(3) concerning having infection with human immunodeficiency virus;
  • revising the factor in subsection 9(4) concerning Epstein-Barr virus;
  • revising the factor in subsection 9(5) concerning having an autoimmune disease;
  • revising the factor in subsection 9(6) concerning transplantation;
  • revising the factor in subsection 9(7) concerning leukaemia;
  • new factor in subsection 9(8) concerning tuberculosis;
  • new definitions of: active tuberculosis disease, one pack year and specified list of autoimmune diseases  in Schedule 1 - Dictionary;

 

Consultation

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to Hodgkin's lymphoma in the Government Notices Gazette of 2 November 2021, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, the Military Rehabilitation and Compensation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority in relation to the investigation.

9.             On 7 March 2023, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority.  This letter emphasised the deletion of the following subfactors; From the specified list of autoimmune diseases; remove coeliac disease, dermatomyositis, primary biliary cirrhosis and Wegener’s granulomatosis. From the specified list of drugs: remove azathioprine, methotrexate and tumour necrosis factor antagonists. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination.  No submissions were received for consideration by the Authority.  No changes were made to the proposed Instrument following this consultation process.

Human Rights

10.         This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.  A Statement of Compatibility with Human Rights follows.

 

Finalisation of Investigation

11.         The determining of this Instrument finalises the investigation in relation to Hodgkin's lymphoma as advertised in the Government Notices Gazette of 2 November 2021.

References

12.         A list of references relating to the above condition is available on the Authority's website at: www.rma.gov.au. Any other document referred to in this Statement of Principles is available on request to the Repatriation Medical Authority at the following address:

              

Email:    info@rma.gov.au

Post:      The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 71 of 2023

Kind of Injury, Disease or Death: Hodgkin lymphoma

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(3) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).  Part XIA of the VEA requires the determination of these instruments outlining the factors connecting particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have Hodgkin lymphoma;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must exist before it can be said that, on the balance of probabilities, Hodgkin lymphoma is connected with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
  • replaces Instrument No. 36 of 2014; and
  • reflects developments in the available sound medical-scientific evidence concerning Hodgkin lymphoma which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

 

 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICESCR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICESCR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and
  • ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Statement of Principles concerning Hodgkin lymphoma (Balance of Probabilities) (No. 71 of 2023), enacted under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, addresses the gap in the assessment and compensation of Hodgkin lymphoma cases related to military service. The Repatriation Medical Authority, pursuant to the Veterans' Entitlements Act, has determined this Statement of Principles to better reflect the current medical-scientific evidence regarding the connection between Hodgkin lymphoma and particular kinds of military service. This legislative instrument outlines the specific factors that must be present to establish a link between Hodgkin lymphoma and military service, facilitating both the claims process for veterans and the review mechanisms available under the Acts. The purpose of this instrument is to ensure that the assessment of claims related to Hodgkin lymphoma is based on the most recent and sound medical-scientific evidence. This ensures that the benefits and compensations under the Acts are both reasonable and proportionate. The Authority consulted with relevant organisations and individuals before finalising the instrument, ensuring that the principles are both comprehensive and reflective of current medical understanding. The instrument is compatible with human rights as it promotes the rights of veterans and service personnel without derogation from any international human rights standards.

Scope and Application

The Statement of Principles concerning Hodgkin lymphoma (Balance of Probabilities) (No. 71 of 2023) applies to veterans, current and former Defence Force members, and their dependants who may have contracted Hodgkin lymphoma as a result of their service. This legislative instrument is determined under subsection 196B(3) of the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, facilitating claims for medical treatment and compensation related to Hodgkin lymphoma. The Statement of Principles outlines the medical-scientific evidence required to establish a connection between Hodgkin lymphoma and service, replacing the previous Instrument No. 75 of 2014. It specifies factors such as tobacco smoking, obesity, infections, and autoimmune diseases that must exist to substantiate a claim. The Instrument has a national jurisdictional reach across Australia and is applicable to both Commonwealth and state/territory jurisdictions. It does not introduce any exclusions, exemptions, or thresholds but rather reflects the latest medical-scientific evidence and has been determined following consultations with relevant organisations and stakeholders. The Authority ensures the compatibility of this Legislative Instrument with human rights by promoting the rights of veterans and Defence Force members, ensuring non-discriminatory access to benefits and medical treatment.

Key Provisions

The Statement of Principles concerning Hodgkin lymphoma (Balance of Probabilities) (No. 71 of 2023) (the Instrument) outlines the circumstances under which a claimant may be entitled to medical treatment and compensation for Hodgkin lymphoma if it is connected to their service. This Instrument is determined under subsection 196B(3) of the Veterans' Entitlements Act 1986 (VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA). The Instrument specifies the factors that must exist for a connection to be made between Hodgkin lymphoma and the service of a person, whether it be eligible war service, defence service, or peacetime service. The Instrument was developed following an investigation into Hodgkin's lymphoma, and it replaces the previous Statement of Principles (Instrument No. 75 of 2014). The Repatriation Medical Authority considered sound medical-scientific evidence, including that previously examined, to determine the factors relevant to establishing a connection between Hodgkin lymphoma and service. The Instrument also includes new factors such as tuberculosis and updated definitions of relevant terms. The Instrument imposes obligations on claimants to provide evidence of their service and the presence of the specified factors, and it requires the Repatriation Commission and the Military Rehabilitation and Compensation Commission to assess claims based on the criteria set out in the Instrument. It also outlines the process for review of decisions by the Veterans' Review Board and the Administrative Appeals Tribunal. The Instrument does not require any specific actions from the parties other than to adhere to the criteria for claim assessment and review processes. Breach of the provisions of the Instrument could have legal consequences for claimants who provide false or misleading information in their claims, potentially leading to civil or criminal penalties. For example, knowingly making a false statement in a claim could be an offence under section 217 of the VEA, which carries a maximum penalty of $13,200 or two years imprisonment, or both. Additionally, if the Repatriation Commission or the Military Rehabilitation and Compensation Commission fails to comply with the requirements of the Instrument in assessing claims, they could be subject to judicial review, and any decisions found to be in breach of the Instrument could be overturned. The Instrument itself does not specify penalties but refers to existing provisions in the VEA and MRCA for handling breaches.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Act
Concepts
Definitions & Interpretation
Reporting & Disclosure Obligations
Rights & Protections

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.